Get the Stockscreener App
1.30
4.41%
-0.06
Pre-market:
1.30
Artelo Biosciences Inc stock is traded at $1.30, with a volume of 151.81K.
It is down -4.41% in the last 24 hours and down -29.35% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
See More
Previous Close:
$1.36
Open:
$1.35
24h Volume:
151.81K
Relative Volume:
0.04
Market Cap:
$4.53M
Revenue:
-
Net Income/Loss:
$-13.47M
P/E Ratio:
-0.0334
EPS:
-38.9215
Net Cash Flow:
$-8.38M
1W Performance:
-2.26%
1M Performance:
-29.35%
6M Performance:
-76.32%
1Y Performance:
-93.98%
1-Day Range:
$1.29
$1.35
1-Week Range:
$1.26
$1.37
52-Week Range:
$1.19
$85.80
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.30 | 4.53M | 0 | -13.47M | -8.38M | -38.92 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Artelo Biosciences discloses positive ART26.12 metabolite profile - grafa.com
Artelo Biosciences reports favorable metabolism... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success - The Manila Times
In human study, Artelo pain drug shows only three metabolites - Stock Titan
Artelo Biosciences Company Profile & Introduction - Moomoo
Artelo Biosciences, Inc. - MLQ.ai
[ARS] ARTELO BIOSCIENCES, INC. SEC Filing - Stock Titan
Artelo Biosciences (NASDAQ: ARTL) proxy seeks large boost in authorized shares - Stock Titan
ARTL Stock Price, Quote & Chart | ARTELO BIOSCIENCES INC (NASDAQ:ARTL) - ChartMill
ARTL Stock Chart | ARTELO BIOSCIENCES INC (NASDAQ:ARTL) - ChartMill
Artelo Biosciences Launches Flexible At-The-Market Offering - The Globe and Mail
Artelo Biosciences, Inc. Announces At The Market Offering Agreement With H.C. Wainwright & Co - Minichart
Artelo Biosciences stock tumbles on $6.5M share offering - Investing.com
Artelo Biosciences Launches $6.53 Million ATM Equity Program With H.C. Wainwright - TradingView
[8-K] ARTELO BIOSCIENCES, INC. Reports Material Event - Stock Titan
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results - Benzinga
Artelo Biosciences stock tumbles on $6.5M share offering By Investing.com - Investing.com Nigeria
Artelo Biosciences to offer up to $6.53 million in common stock via H.C. Wainwright - marketscreener.com
Artelo Biosciences To Offer Up To $6.53 Million In Common Stock Via H.C. Wainwright - TradingView
Artelo Biosciences (ARTL) asks shareholders to approve 500M-share authorization - Stock Titan
Artelo Biosciences (ARTL) launches $6.53M at-the-market program with HCW - Stock Titan
Tuesday's session: top gainers and losers - ChartMill
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
ARTL Stock In Focus As Artelo Biosciences Taps AI For Drug Pipeline - StocksToTrade
ARTL - Finviz
Artelo Biosciences ARTL Jumps On AI Drug Discovery Pact - timothysykes.com
Which stocks are moving before the opening bell on Tuesday? - ChartMill
Wondering what's happening in today's after-hours session? - ChartMill
Why did ARTL stock skyrocket over 141% pre-market today? - MSN
Trending Stocks Today | Artelo Biosciences Soars 69.19% Post-Market - Moomoo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
[EFFECT] ARTELO BIOSCIENCES, INC. SEC Filing - Stock Titan
Avis Budget Group, Toyota Motor and other big stocks moving lower in Monday's pre-market session - MSN
Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Sahm
ARTL (NASDAQ: ARTL) terminates $6.5M ATM; sold 50,858 shares for $451.5K - Stock Titan
Trending Industry Today: Artelo Biosciences Leads Losses In SOL Reserve Concept Stocks - Moomoo
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Artelo Biosciences Ends ATM Offering, Shifts Financing Strategy - The Globe and Mail
Artelo Biosciences to terminate at-the-market offering agreement effective May 18, 2026SEC filing - marketscreener.com
Artelo Biosciences (NASDAQ: ARTL) ends $6.5M at-the-market stock program - Stock Titan
Artelo Biosciences | SCHEDULE 13G: Others - Moomoo
Armistice Capital (ARTL) reports 235,823 shares, 9.99% stake - Stock Titan
Artelo Biosciences (NASDAQ: ARTL) widens Q1 loss but boosts liquidity - Stock Titan
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results - Yahoo Finance
Artelo Biosciences (ARTL) amends S-3; Exhibit 4.3 filed, fees noted - Stock Titan
Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug - MSN
Artelo Biosciences Provides Business Update Outlining - GlobeNewswire
TradingKey - TradingKey
Artelo Biosciences Stock Soars 114% After Promising Depression Treatment Data - MSN
Why is ARTL stock soaring pre-market today? - MSN
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):